But with FDA action, it would be the third vaccine against Covid-19 to receive full FDA approval ... process for the Novavax vaccine, like all vaccines is based solely on ensuring safety and efficacy, ...

The delay follows leadership changes within the FDA. Dr. Scott Steele has been appointed acting director of the agency’s ...

In the wake of unprecedented workforce cuts at the FDA, former Commissioner Scott Gottlieb and an unnamed former CBER ...

Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why ...

After the gutting of the Department of Health and Human Services, fears mount about the future direction of the FDA—with ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

One of the FDA’s recently departed top officials is weighing in on the wide-ranging staff cuts at the agency and how they ...

Health secretary Robert F. Kennedy Jr. has expressed another unorthodox view on vaccines, declaring that single antigen ...

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID ...

But full FDA approval would allow the vaccine to ... alternative to mRNA COVID-19 vaccines for the US,” Novavax added. The delay comes as the FDA is undergoing leadership changes.

The delay dovetails with moves by Republican lawmakers in at least seven states to ban or limit mRNA vaccines. Some, according to KFF Health News, are also pressing regulators to revoke federal ...